65438+1October 5, 265438+Business Herald of the 20th century It was learned from the Ministry of Industry and Information Technology that at present, three enterprises, Sinopharm Zhongsheng Beijing Company, Sinopharm Zhongsheng Wuhan Company and Beijing Kexing Zhongwei Company, have completed the task of capacity building in 2020 and have all the conditions for large-scale production. Their vaccine production has started an "accelerated" mode, and the company's personnel are working with high intensity and full load, racing against time.
Among them, the COVID-19 inactivated vaccine production capacity of Sinopharm Zhongsheng Beijing Company in 2002 1 year can reach more than1100 million doses, and the annual production capacity will be increased to more than 600 million doses after the second production line of Kexing Zhongwei is put into use. The production capacity of these two companies alone exceeds 654.38+06 billion doses.
At present, Malaysian, Turkish, Philippine and Mexican countries have ordered China vaccine, and Indonesian, Pakistani and Mexican countries have also signed agreements with China to produce vaccine. At the initial stage of marketing, there may be a gap between the supply and demand of vaccines in China.
However, according to the data of the Ministry of Industry and Information Technology, at present, 18 domestic enterprises have successively built vaccine production capacity in COVID-19. With the further improvement of the production capacity of inactivated vaccine in COVID-19 and the gradual completion of the production capacity construction of other technical routes, the production capacity of vaccine in COVID-19, China can meet the domestic demand for large-scale vaccination.
According to the Ministry of Industry and Information Technology, on February 30th, 2020, the inactivated COVID-19 vaccine of Sinopharm Zhongsheng Beijing Company 65438 was approved by the State Medical and Drug Administration for conditional listing. Previously, COVID-19 inactivated vaccines of Sinopharm Zhongsheng Wuhan Company and Beijing Kexing Zhongwei Company were approved for emergency use, and the vaccines of these three companies have started to inoculate key populations.
According to the Ministry of Industry and Information Technology, in order to meet the vaccination needs of key populations in COVID-19 at this stage, Sinopharm Zhongsheng Beijing Company, Sinopharm Zhongsheng Wuhan Company and Beijing Kexing Zhongwei Company started the "accelerated" mode. During the New Year holiday, they will not stop production, and employees will work at full capacity and organize production around the clock.
Among them, in 2002 1 year, the production capacity of COVID-19 inactivated vaccine of Sinopharm Zhongsheng Beijing Company can reach more than1100 million doses. Sinopharm Zhongsheng Wuhan Company and Beijing Kexing Zhongwei Company are also making every effort to speed up the expansion of production capacity and ensure the vaccination demand in COVID-19.
Max Zhang, director of COVID-19 Inactivated Vaccine Project of Sinopharm Zhongsheng Beijing Company, recently introduced that one packaging line of this company can package 200,000 doses every day. In order to promote more vaccines to be listed before the Spring Festival, its employees have given up rest days and worked 24 hours a day.
Liu Peicheng/KLOC-0, spokesperson of Kexing Holding Biotechnology Co., Ltd., told the reporter of 2 1 Century Business Herald on October 5 that the annual production capacity of COVID-19 vaccine production line that Kexing Zhongwei has built and put into use exceeds 300 million doses, and the annual production capacity will be increased to more than 600 million doses after the second phase of production line is put into use recently. "According to the market demand and available funds, the company may further expand its production capacity in the future, which will make the global COVID-19 vaccine accessible and affordable.
In addition, Beijing Kexing Zhongwei recently received an investment of more than US$ 500 million from China Biopharmaceutical for further research and development, capacity expansion and production of novel coronavirus inactivated vaccine Kelaifu.
According to the Ministry of Industry and Information Technology, preparations for mass production of vaccines in COVID-19 are in full swing. On the one hand, a special class for vaccine production guarantee in COVID-19 was set up to track and dispatch the production capacity and output of key enterprises every week; On the other hand, enterprises of all technical routes are required to simultaneously promote capacity building; In addition, the Ministry of Industry and Information Technology also guides enterprises to judge and analyze the supply risks of production materials, promotes the research on production technology of key materials, and organizes upstream and downstream enterprises to strengthen the docking of supply and demand, so as to ensure the stability of the vaccine production supply chain in COVID-19.
It is worth noting that on June 5, 438+February 3, 2020/KLOC-0, Wang Jiangping, Vice Minister of the Ministry of Industry and Information Technology, went to Sinopharm Zhongsheng Beijing Company and Beijing Kexing Zhongwei Company again to investigate the vaccine production capacity construction in COVID-19. He stressed that it is necessary to steadily accelerate the expansion of production capacity, scientifically arrange production plans, maximize production potential, and do a good job in ensuring vaccine production and supply in COVID-19 on the premise of ensuring vaccine quality and safety.
According to the Ministry of Industry and Information Technology, three enterprises, Sinopharm Zhongsheng Beijing Company, Sinopharm Zhongsheng Wuhan Company and Beijing Kexing Zhongwei Company, have completed the task of capacity building in 2020 and have all the conditions for large-scale production. The capacity building of other enterprises is also progressing in an orderly manner as planned. At present, there are 18 domestic enterprises building vaccine production capacity in COVID-19.
In the next step, our department will continue to strengthen the production scheduling, and promote enterprises to further expand their production capacity through a series of ways, such as the transformation of production workshops and the upgrading of production technology, so as to comprehensively organize and guarantee vaccine production in COVID-19.
At the press conference of the joint prevention and control mechanism in the State Council on June 5438+February 3/KLOC-0, 2020, Ceng Yixin, deputy director of National Health Commission and head of the vaccine research and development team of the joint prevention and control mechanism in the State Council, said that China planned to establish a national immune barrier through vaccination. The basic attribute of vaccine is that it belongs to public products, and the price may change according to the amount used. But a major premise is that it must be provided free of charge by the whole people.
Shen Bo, director of the International Department of the Ministry of Foreign Affairs, said, "After the research and development of China COVID-19 vaccine is completed and put into use, it will firmly fulfill its promise to make the vaccine a global public product and supply it to the world at a fair and reasonable price."
It is worth noting that China vaccine has been ordered by Malaysian, Turkish, Philippine and Mexican countries. Indonesian, Pakistani and Mexican countries have signed agreements with China to produce vaccines.
So, can the vaccine production capacity in China and even the whole world meet these demands?
A person in charge of Sanofi Pasteur vaccine in China calculated an account for 265438+20th Century Business Herald: There are about 7.5 billion people in the world today, and it takes about 70% people, that is, 5.2 billion people, to form population immunity worldwide. Most vaccines need two or even three injections, which means that at least 654.38 billion doses of COVID-19 vaccine are needed.
"This means that while ensuring the supply of other vaccines, the production capacity of COVID-19 vaccines needs to be tripled on the basis of all existing vaccines, which puts great pressure on vaccine production, cold chain transportation and vaccination."
However, Liu Peicheng pointed out that universal vaccination is not achieved overnight, but is gradually promoted according to various factors such as population, age and demand.
Ceng Yixin also said that the first step of vaccination is to vaccinate key populations and people at high risk of infection. In June this year, China launched the emergency vaccination of COVID-19 vaccine for high-risk groups. By the end of June, 1 1.5 million doses had been inoculated. Subsequently, the vaccination of key populations was officially launched in June 5438+February 65438+May. At present, the cumulative vaccination amount of key populations in China has exceeded 3 million doses.
He introduced that the second step is to gradually expand to high-risk groups, mainly the elderly and people with basic diseases, with the approval of conditional marketing of vaccines and the improvement of vaccine supply capacity. The third step is to expand vaccination to the whole population.
Chen, deputy general manager of CCID Consulting Medical and Health Industry Research Center, told 265438+20 th Century Business Herald, "Before, due to the possibility of clinical failure in vaccine research and development, the large-scale construction of production lines faced high uncertainty. Therefore, after successful vaccine research and development in COVID-19, the initial production capacity may be insufficient, and priority will be given to vaccinating key populations such as the elderly. However, once the research and development is successful, China may speed up the procurement and commissioning of equipment, and the production capacity will increase very quickly. "
Mao Junfeng, deputy director of the Consumer Products Industry Department of the Ministry of Industry and Information Technology, also pointed out at the above conference that the improvement of vaccine production capacity is a dynamic process. In addition to the above inactivated vaccines, the vaccine production capacity of other technical routes is also progressing in an orderly manner as planned. "With the further improvement of inactivated vaccine production capacity in COVID-19 and the completion of other technical routes, the vaccine production capacity in COVID-19, China can meet the domestic large-scale vaccination demand."
It is reported that up to now, five technical routes of 14 vaccines have entered clinical trials in China, and five vaccines from three technical routes have entered phase III clinical trials.
For more information, please download 2 1 financial APP.